Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.44
-0.05-0.44%
Last update: Jun 8, 1:10 PM
Contineum Therapeutics Inc Analyst Ratings
CTNMNASDAQ
Contineum Therapeutics Analyst Ratings and Price Targets | NASDAQ:CTNM | Benzinga
Contineum Therapeutics Inc has a consensus price target of $21.67 based on the ratings of 6 analysts. The high is $29 issued by Stifel on April 30, 2024. The low is $16 issued by Morgan Stanley on May 14, 2026. The 3 most-recent analyst ratings were released by Morgan Stanley, Baird, and Morgan Stanley on May 14, 2026, March 6, 2026, and January 8, 2026, respectively. With an average price target of $16.67 between Morgan Stanley, Baird, and Morgan Stanley, there's an implied 45.69% upside for Contineum Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Baird
RBC Capital
Leerink Partners
Jones Trading
1calculated from analyst ratings
Analyst Ratings for Contineum Therapeutics
Loading calendar...
FAQ
What is the target price for Contineum Therapeutics (CTNM) stock?
The latest price target for Contineum Therapeutics (NASDAQ:CTNM) was reported by Morgan Stanley on May 14, 2026. The analyst firm set a price target for $16.00 expecting CTNM to rise to within 12 months (a possible 39.86% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Contineum Therapeutics (CTNM)?
The latest analyst rating for Contineum Therapeutics (NASDAQ:CTNM) was provided by Morgan Stanley, and Contineum Therapeutics maintained their equal-weight rating.
When was the last upgrade for Contineum Therapeutics (CTNM)?
There is no last upgrade for Contineum Therapeutics
When was the last downgrade for Contineum Therapeutics (CTNM)?
The last downgrade for Contineum Therapeutics Inc happened on January 8, 2026 when Morgan Stanley changed their price target from $23 to $14 for Contineum Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Contineum Therapeutics (CTNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Contineum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Contineum Therapeutics was filed on May 14, 2026 so you should expect the next rating to be made available sometime around May 14, 2027.
Is the Analyst Rating Contineum Therapeutics (CTNM) correct?
While ratings are subjective and will change, the latest Contineum Therapeutics (CTNM) rating was a maintained with a price target of $14.00 to $16.00. The current price Contineum Therapeutics (CTNM) is trading at is $11.44, which is out of the analyst’s predicted range.
